Scott Rocklage, PhD, has been a Managing Partner at 5AM Ventures since 2004. 5AM Ventures is an investment fund focusing on healthcare and pharmaceutical companies. Rocklage brought his nearly three decades of experience in the industry with him when he joined the venture in 2003. He has been involved in three U.S. New Drug Applications and has started many drugs into clinical trials.
Scott’s 30 years of work experience includes serving as Chairman and CEO of Cubist Pharmaceuticals. He was Chairman of the Board at Relvpsa. He acted as President and CEO of Nvcomed Salutar.
He has also worked in Research and Development at several pharmaceutical companies. Rocklage currently serves as Chairman of the Board for Rennovia, Kinestral and Cidara. He is on the boards of several other pharmaceutical companies.
Dr. Rocklage has in-depth experience in the field of pharmaceuticals which makes him a major asset to SAM Ventures. His experience is one of the most extensive in the industry. He received his Bachelor’s Degree in Chemistry from the University of California and his Doctorate from MIT. While there he worked on research projects with Richard Schrock, a Nobel Prize winner in Chemistry.
Rocklage currently holds patents on or co-patents on over 30 products in the U.S. He is based out of Boston, Massachusetts. When asked about 5AM Ventures, he said that his company is focused on businesses in the early stages of formation.
He works with entrepreneurs who are business people, physicians or scientists, and helps them get their ideas into medicines that can treat illnesses that are currently untreated.